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a n a ly s i s CRISPR-Cas genome-editing methods hold immense potential as therapeutic tools to fix disease-causing mutations at the level of DNA. In contrast to typical drug development strategies aimed at targets that are highly conserved among individual patients, treatment at the genomic level must contend with substantial inter-individual natural genetic variation. Here we analyze the recently released ExAC and 1000 Genomes data sets to determine how human genetic variation impacts target choice for Cas endonucleases in the context of therapeutic genome editing. We find that this genetic variation confounds the target sites of certain Cas endonucleases more than others, and we provide a compendium of guide RNAs predicted to have high efficacy in diverse patient populations. For further analysis, we focus on 12 therapeutically relevant genes and consider how genetic variation affects off-target candidates for these loci. Our analysis suggests that, in large populations of individuals, most candidate off-target sites will be rare, underscoring the need for prescreening of patients through whole-genome sequencing to ensure safety. This information can be integrated with empirical methods for guide RNA selection into a framework for designing CRISPR-based therapeutics that maximizes efficacy and safety across patient populations.
The development of CRISPR-based RNA-guided endonucleases, such as Cas9 and Cpf1, for eukaryotic genome editing has sparked intense interest in the use of this technology for therapeutic applications [1] [2] [3] . In contrast to small-molecule therapies, which target highly conserved active sites in proteins, therapies designed to target particular DNA sequences must take into account genetic variation among patient populations. If this variation disrupts the therapy target site, it can affect the efficacy of a CRISPR-based therapeutic; if it generates off-target candidate sites, it can affect the safety of a CRISPR-based therapeutic. Previously, it has been reported that genetic variation in cell lines can alter Cas9 targeting 4 , but there has been limited effort to comprehensively and systematically evaluate this phenomenon in large human populations.
As CRISPR-based therapies advance toward human clinical trials, it is important to consider how natural genetic variation in the human population may affect the results from these trials and even patient safety. Recently, large-scale sequencing data sets from the Exome Aggregation Consortium (ExAC) and 1000 Genomes Project have provided an unprecedented view of the landscape of human genetic variation [5] [6] [7] [8] . These data sets have captured nearly all common variants in the human population and contain deep coverage of rare variants 5, 8 , enabling evaluation of the effects of human variation on therapeutic genome editing in diverse human populations. Here we use these data sets to determine the impact of population genetic variation on therapeutic genome editing with Streptococcus pyogenes Cas9 (SpCas9), the SpCas9 variants VQR and VRER, Staphylococcus aureus Cas9 (SaCas9), and Acidaminococcus sp. Cpf1 (AsCpf1) [1] [2] [3] 9, 10 . We found extensive variation likely to impact the efficacy of these enzymes and propose that unique, patient-specific off-target candidates will be one of the main challenges in ensuring the safety of these therapeutics. These results provide a framework for designing CRISPR-based therapeutics, highlight the need to develop multiple guide RNA-enzyme pairs for each target locus, and suggest that pretherapeutic whole-genome sequencing will be required to ensure uniform efficacy and safety for treatment across patient populations.
RESULTS

Human genetic variation impacts choice of Cas enzyme
To date, two families of class 2 (single-effector) CRISPR nucleases, Cas9 and Cpf1, have been harnessed for eukaryotic genome editing [1] [2] [3] 11 . Both Cas9 and Cpf1 are programmed by guide RNAs, which direct cleavage of DNA targets that are complementary to the guide RNA target and flanked by a short protospacer-adjacent motif (PAM) specific to each endonuclease 3, 12 (Fig. 1a) . Mismatches between the guide RNA and its DNA target have been shown to decrease RNA-guided endonuclease activity, and deviation from the canonical PAM sequence often completely abolishes nuclease activity [13] [14] [15] [16] . The recently released ExAC data set, with variants from 60,706 individuals, contains on average one variant for every 8 nucleotides (nt) in the human exome 5 . To assess the impact of this variation on guide RNA efficacy, we used the ExAC data set to catalog variants present among all possible targets in the human reference exome that either (i) disrupt the target PAM sequence or (ii) introduce mismatches between the guide RNA and the genomic DNA, which we collectively term 'target variation' (Fig. 1a) . a n a ly s i s
In addition to two orthologs of Cas9 (SpCas9 and SaCas9) and Cpf1, a number of SpCas9 variants have been engineered as tools for genome editing, with each using a different PAM 1-3,9,10 ( Table 1) . Consideration of multiple enzymes with different PAM requirements will increase the number of available genomic targets for therapeutic loci. We therefore assessed variation at each PAM in the human exome for SpCas9-WT (wild type; 5′-NGG-3′), SpCas9-VQR (5′-NGA-3′), SpCas9-VRER (5′-NGCG-3′), SaCas9-WT (5′-NNGRRT-3′), and AsCpf1-WT (5′-TTTN-3′) (where N is any nucleotide and R is A or G)-all of which are currently being considered as candidate enzymes for development as CRISPR-based therapeutics. The recently reported enhanced-specificity Cas9 (eSpCas9) and high-fidelity SpCas9 (SpCas9-HF) have the same 5′-NGG-3′ PAM as SpCas9-WT and are thus not considered separately here 17, 18 . For each nuclease, we determined the fraction of exonic PAMs containing variants that alter PAM recognition either through abolishing the existing PAM or creating a new one relative to the reference genome. In the ExAC population, the total fraction of targets containing PAM-altering variants was similar for all enzymes (21-35%) except SpCas9-VRER, for which 80% of targets were affected by PAM-altering variants ( Table 1 and Supplementary Fig. 1 ). The PAM for SpCas9-VRER contains a CpG motif, which has been shown to be highly mutable 5 . In accordance with these results, we found that CG was the most highly mutable 2-nt PAM motif in the human exome, and 66% of cytosine and guanine nucleotides present in CpG motifs showed variation in the 60,706 ExAC individuals 5 (Fig. 1b,c and Supplementary Table 1) . These results suggest that enzymes using PAMs containing CG motifs are considerably more affected by target variation in the human genome.
Low-variation regions of the human exome are more reliably targeted We extended our analysis to determine the fraction of all possible targets of SpCas9-WT, SpCas9-VQR, SaCas9-WT, and AsCpf1-WT in Allele frequency bin (%) Cumulative allele frequency (%) the human exome that contain variants. We found that 93-95% of targets contained variants in the ExAC data set that are likely to alter the efficiency of target cleavage (Fig. 1d ,e and Supplementary Table 2) , and most target variation occurring at frequencies of <0.1% was heterozygous ( Fig. 1d ,f and Supplementary Table 2 ). The ExAC data set is large enough that it provides near-comprehensive coverage of variants at allele frequencies of ≥0.01% in the population (i.e., variation that will exist in at least 1 out of 10,000 alleles in the population) 5 . Hence, we used this data set to compile a list of exome-wide target sites for SpCas9-WT, Cas9-VQR, SaCas9-WT, and AsCpf1-WT lacking variants occurring at an allele frequency of ≥0.01% (referred to as 'platinum' targets; whole-exome platinum targets for each enzyme are given in Supplementary Data). These platinum targets should be efficacious in ≥99.99% of the population ( Fig. 2 ; target variation <0.01%).
For further analysis, we selected 12 therapeutically relevant genes, including those that are currently the focus of therapeutic development: CEP290, CFTR, DMD, G6PC, HBB, IDUA, IL2RG, PCSK9, PDCD1, SERPINA1, TTR, and VEGFA (Supplementary Fig. 2 ; platinum targets for each enzyme for these 12 genes are given in Supplementary Data). For these 12 genes, approximately two-thirds of the possible exonic targets met our platinum criteria, with PCSK9 containing the smallest fraction of platinum targets (50%) (Supplementary Table 3 ). This finding suggests that, for most genomic regions, ample platinum targets will exist that can be considered when beginning the process of therapeutic target selection.
We observed that both high-variation targets and platinum targets clustered along exons for each of the 12 genes examined. For example, all targets in the 5′ half of PCSK9 exon 4 were platinum, whereas very few platinum targets existed for exon 5 (Fig. 2c) . However, even for regions of high-frequency variation, such as PCSK9 exons 1-4, it was still possible to find small numbers of platinum targets for some enzymes (Fig. 2c) . This observation for PCSK9 is representative of the findings for the other genes investigated in this study and suggests that considering multiple enzymes with distinct PAM requirements increases the likelihood of finding a platinum target. In the event that a genomic region of interest contains variation that cannot be avoided, it will be necessary to design multiple guide RNAs, each tailored to accommodate the presence of high-frequency (≥0.01% allele frequency) variants.
Low-frequency off-target candidates predominate in large populations A second major consideration in CRISPR-based therapeutics is safety, which can be improved by designing guide RNAs with minimal potential off-target activity. Unbiased investigation of genome-wide CRISPR nuclease activity suggests that most off-target activity occurs at loci with ≤3 mismatches with respect to the guide RNA sequence 9, 13, [19] [20] [21] [22] [23] [24] . Current approaches for Cas9 target selection rank off-target candidates found in the reference human genome by both the number and position of guide RNA mismatches, under the assumption that loci containing ≤3 mismatches or containing PAM-distal mismatches are more likely to be cleaved [13] [14] [15] . However, in a population of individuals, this strategy is complicated by the existence of multiple haplotypes (sets of variants that co-occur), which will have different positions or numbers of mismatches at candidate off-target sites (Fig. 3a) . To assess the predicted safety of a guide RNA within a population, we used the 1000 Genomes data set, which includes phased single-nucleotide variant calls for 2,504 individuals 8 . From these data, we reconstructed allele-specific whole-genome sequences for each individual. In contrast with the much larger ExAC data set, which collapses all variants, the 1000 Genomes data set contains information about haplotypes, which enabled us to identify off-target sites in the population arising from single or multiple variants in an individual haplotype. For platinum targets in the 12 genes considered here, we quantified off-target candidates (defined as genomic loci with ≤3 mismatches with respect to a given guide RNA) arising from all 1000 Genomes haplotypes (Supplementary Data). In this relatively small population of 2,504 individuals, more than half of the haplotypes containing off-target candidates were present in ≥10% of individuals (Fig. 3b) . However, for haplotypes present in <10% of individuals, the number of off-target candidates for each guide RNA increased with decreasing haplotype frequency (Fig. 3b) . This trend indicates that, for large populations, most unique off-target candidates for a given guide RNA will differ between individuals, as shown by the rise in the cumulative number of off-target candidates for an individual guide RNA accompanying decreasing allele frequency (Fig. 3c) .
Avoiding high-frequency off-target candidates should maximize population safety For individual guide RNAs in the 12 genes we analyzed, we found that the number of off-target candidates for SpCas9-WT, SpCas9-VQR, SaCas9-WT, and AsCpf1-WT varied from 0 to greater than 10,000 in the 1000 Genomes population (Fig. 3d) . Much of this disparity reflects how unique or repetitive an individual target sequence is within the human genome. For instance, SaCas9-WT, which has a longer PAM and hence fewer genomic targets, had on average fewer off-target candidates per guide RNA. Of the 12 genes we considered, some contain more repetitive regions relative to the rest of the human genome, as reflected by increased numbers of targets with high offtarget candidate counts (Fig. 4a) . For example, within PCSK9 exons 2-5, we observed that platinum targets with high and low numbers of off-target candidates tended to cluster in regions of sequence that were repetitive and unique within the genome, respectively (Fig. 4b) . This pattern held true for all 12 genes studied. Interestingly, within repetitive regions of exons, we did identify small numbers of platinum targets with substantially reduced quantities of n specifies the number of protein-coding targets in the human exome for each enzyme. Orientation refers to the location of the PAM relative to the guide-RNA-complementary region of the target, and allele frequencies refer to the percentage of the ExAC population containing a particular PAM-altering variant for a given target in the human exome. a n a ly s i s 1 0 9 8 VOLUME 23 | NUMBER 9 | SEPTEMBER 2017 nature medicine off-target candidates. These findings further support the notion that using multiple enzymes with distinct PAM requirements should enhance both safety and efficacy by increasing the number of available targets for therapeutically relevant genomic loci.
Additionally, in a population, the number of off-target candidates at a given locus is compounded by the existence of multiple haplotypes, the number of which will increase with the size of the population. Hence, for each off-target candidate present in a high-frequency haplotype, in a large population multiple lower-frequency haplotypes are likely to exist that may lead to different gene-editing outcomes. Thus, minimizing the number of off-target candidates occurring in high-frequency haplotypes is of critical importance for the selection of therapeutic guide RNAs. The current 1000 Genomes data set provides comprehensive coverage of alleles occurring at a frequency of up to 0.1% in the population (considered to be the lower bound for high-frequency variants), allowing the identification of platinum targets with minimal off-target candidates in high-frequency haplotypes in the human population 5, 8 . Use of the enhanced-specificity enzymes eSpCas9 and Cas9-HF1 will further reduce the likelihood of cleavage at offtarget candidate sites, but it will still remain important to avoid target regions that are repetitive or have off-target candidates in highfrequency haplotypes 17, 18 .
Consideration of patient populations
Genome-editing therapies are currently being designed for a range of applications, including treatment of rare genetic diseases (for example, Leber's congenital amaurosis) and common conditions (for example, high cholesterol), and therapeutic augmentation whereby a genetic change increases the efficacy of a treatment (for example, PDCD1 knockout for enhanced immunotherapy). Each of these applications will have a unique patient population with its own landscape of genetic variation, and this can be considered when choosing therapeutic targets. For example, Tay-Sachs disease occurs in Ashkenazi populations at more than ten times the rate that it occurs in the general population 25 ; because of the shared genetic heritage among people with Tay-Sachs disease, there will be fewer variants in the population of affected individuals and those that are present will occur at a higher frequency. On the other hand, populations of patients who have diverse genetic backgrounds will contain large numbers of variants that occur at high frequencies in a subset of the population but at low frequencies overall. The 1000 Genomes Project provides demographic information, including sex and ancestry, for each individual, so we used these data to explore how much off-target candidate variation for a given individual was explained by population demographics. For all off-target candidates for the guide RNAs targeting the 12 genes considered here, we performed principal-component analysis (PCA) and found that the first five principal components separated individuals most effectively by continent but also by subcontinent and sex ( Fig. 4c and Supplementary Figs. 3-5) . We found that these first five principal components accounted for 12% of the variation in off-target candidates occurring at a frequency of <100% among members of the population, indicating that the safety and efficacy of therapeutics can be enhanced by designing therapeutic targets for subpopulations of patients with specific variants.
DISCUSSION
Ideally, personalized genomic medicine would utilize tailored RNAguided endonuclease therapeutics for each patient. However, in most cases, the cost and time required to obtain regulatory approval for each individualized therapeutic would be prohibitive given the current regulatory framework. Instead, a small number of carefully chosen enzyme-guide combinations may be developed and tested to provide a suite of potential therapeutics for a particular patient population. Current methods for selecting targets and guides typically rely solely on sequence information from the human reference genome and criteria obtained from empirical tests of efficacy. However, although guide RNA efficacy does vary and can be difficult to predict, if therapeutic targets are selected on the basis of efficacy alone, those therapies run the risk of being mired in a clinical trial with confounding results and/or undesirable outcomes due to human genetic variation. Our findings regarding the impact of genetic variation on Cas endonuclease activity can be integrated with empirical methods to streamline the design and testing of genome-editing therapeutics in a consolidated framework (Fig. 4d) . First, when possible, regions of low variation should be targeted, which will ensure maximal efficacy across a patient population with diverse genetic backgrounds. Second, guide RNAs need to be selected to minimize the number of off-target candidates occurring on high-frequency haplotypes in the patient population to reduce the likelihood of off-target mutations resulting in oncogenic events or undesirable side effects. Third, assessing the amount of low-frequency variation present in the patient population can be helpful for estimating the number of guide RNA-enzyme combinations required to effectively and safely treat the anticipated patient population. This will be particularly important when designing targets for use within specific populations. For example, for treatment of common diseases, more guide RNA-enzyme combinations will need to be developed given the breadth of the natural genetic variation in the patient population. Fourth, in silico screening and empirical assays 9, [19] [20] [21] [26] [27] [28] to assess target efficacy and genome-wide specificity should be used to identify the optimal guide RNA-enzyme combinations from the pool of selected guide RNAs. In the event that no high-efficacy guides are found, the number of guide RNA-enzyme combinations should be increased and tailored to the presence of multiple independent high-frequency haplotypes. The safety of selected combinations of guide RNA and enzyme should be evaluated through unbiased whole-genome off-target detection in relevant cell lines (ideally patient specific). Combinations that pass all of these filters should then be moved forward for regulatory approval. Finally, a n a ly s i s pretherapeutic whole-genome sequencing of individual patients will be needed to select a single approved guide RNA-enzyme combination for treatment that is a perfect match to the patient's genome and free of patient-specific off-target candidates. The selection of specific targets to pursue for therapeutic development will also depend on the type of gene edit desired. For example, gene-knockout strategies (which are being pursued using PDCD1 for immunotherapy and PCSK9 for treatment of cardiovascular disease) have many guide choices, and researchers can choose from a range of low-frequency target regions within or near the gene of interest and then select the guide within that subset that provides the most efficient gene knockdown. Other diseases can be addressed by removal of single or multiple causal variants, and therapies are being developed that aim to remove mutated segments of genes to restore function (for example, CEP290 for Leber's congenital amaurosis and DMD for Duchenne muscular dystrophy). While this strategy for therapeutic intervention also affords some flexibility in target selection, researchers will be limited to working with a single enzyme because two guide RNAs are needed for each gene, reducing the number of target options; this strategy carries the risk of doubling the number of potential off-target candidates as well. Finally, homology-directed repair (HDR) is being used for correction of disease-causing mutations affecting mitotically active cells in the body (such as SERPINA1 for alpha-1 antitrypsin and CFTR for cystic fibrosis). In HDR strategies, Cas nucleases are used to cleave the target gene typically within 10-20 nt of the desired integration site, greatly restricting the targetable range. However, considering SpCas9, SpCas9-VQR, SaCas9, and AsCpf1, a target is present at approximately every 4 nt in the human exome, which should allow selection of a low-variation region even in situations with a narrow target range, which would be required by HDR.
Continued technological development will deliver more powerful and precise systems for therapeutic genome editing. Beyond nuclease-based strategies, new approaches that leverage the programmable DNA-binding activity of CRISPR-based enzymes to direct DNA basemodifying enzymes, such as base editing 29 , also promises to further expand therapeutic options. Finally, well-designed clinical trials that are carried out efficiently and smoothly will be central to addressing the regulatory and ethical challenges facing therapeutic genome editing. Failure to anticipate the genetic diversity in patient populations will confound clinical trials and may lead to adverse outcomes. Our analysis of the impact of human genetic variation on CRISPR-Casbased therapeutics provides a toolset and resources that will increase the efficacy and safety of these therapies, ultimately moving them more quickly toward the clinic.
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